Published in final edited form as:

Tetrahedron Lett. 2006 November 6; 47(45): 7893–7896. doi:10.1016/j.tetlet.2006.09.015.

Transannular Anti-Michael Addition: Formation of 4H-Pyrazolo[5,1-c]thiazines

Yat Fan Suen[†], Håkon Hope[†], Michael H. Nantz[‡], Makhluf J. Haddadin^{⊥,‡}, and Mark J. Kurth^{†,*}

[†]Department of Chemistry, University of California, Davis, CA 95616, USA

[‡]Department of Chemistry, University of Louisville, Louisville, KY 40292, USA

[⊥]Department of Chemistry, American University of Beirut, Beirut, Lebanon

Abstract

The reaction of 2-(diphenylmethylene)thietan-3-one (**2**) with 1,2,4,5-tetrazines (**3a–c**) in KOH/MeOH/THF gives 4H-pyrazolo[5,1-c]thiazines (**7a–c**). This novel condensation reaction proceeds via the intermediacy of an 8-(diphenylmethylene)-2H-1,4,5-thiadiazocin-7(8H)-one (**5**), which undergoes a multi-step rearrangement including a rare anti-Michael addition.

Keywords

Anti-Michael Addition; Pyrazole; 4H-Pyrazolo[5,1-c]thiazine

The synthesis of multiply-substituted pyrazoles has received considerable attention because of their diverse applications in both the pharmaceutical and the agrochemical industries.¹ In a serendipitous way, we became interested in the synthesis of fully substituted pyrazoles and recently reported the finding that thietanone **1** reacts, under mild basic conditions in alcoholic solvent, with 1,2,4,5-tetrazines **3a–c** to yield pyrazole **6a–c** (Scheme 1).² We hypothesized that formation of pyrazole **6** proceeded through the ring contraction/desulfurization of intermediate **5**. This hypothetical 8-benzylidene-2H-1,4,5-thiadiazocin-7(8H)-one forms in analogy to the reaction of cyclobutanone with **3** which under similar conditions yields isolable 1,2-diazocin-4-ones (**5'** in Scheme 1).³ It is believed that this multistep transformation of **5** to **6** is initiated by the Michael addition of an alkoxide ion (generated from solvent; R² = CH₃, CH₂CH₃, CH₂CH₂OH) to the benzylidenone moiety.

Based upon these insights, the purpose of this work was to manipulate the starting thietanone in such a way that the resulting 1,4,5-thiadiazocinone derivative (**5**) would be stable. It was envisaged that introduction of an additional phenyl ring at the exo-cyclic double bond (e.g., thietanone **2**) would lead to isolable analogs of **5** (R¹ = C₆H₅) by

© 2006 Elsevier Ltd. All rights reserved

*Corresponding author. Tel.: (530) 752-8192; Fax: (530) 752-8995; mjkurth@ucdavis.edu.

[‡]M.J.H. dedicates this work to Dr. Mary Kasparian for her distinguished career of chemistry teaching and high standards at the American University of Beirut.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

retarding the rate of alkoxide addition to the now more hindered Michael acceptor. The requisite 2-(diphenylmethylene)thietan-3-one (**2**) was prepared⁴ as outlined in Scheme 2.

In the event, reaction of **2** with 1,2,4,5-tetrazine **3a** delivered a stable product consistent in molecular weight with the targeted 1,4,5-thiadiazcinone **5a** ($R^1 = C_6H_5$). However, there were a number of surprises in the spectral data of this product vis-à-vis the anticipated 1,4,5-thiadiazcinone – principal among these being the presence of a unexchangeable, sharp one proton singlet in its 1H NMR at 5.85 δ in addition to the absence of methylene protons as confirmed by the lack of ^{13}C NMR alkyl carbons holding protons. 1,2,4,5-Tetrazines **3b** and **3c** gave similar products. Fortunately, the product from the reaction of **2** with **3c** gave X-ray crystallographic quality crystals, which established the product as 4*H*-pyrazolo[5,1-*c*]thiazine **7c** (Figure 1).

4*H*-Pyrazolo[5,1-*c*]thiazines **7a–c** are fully substituted pyrazoles wherein a sulfur-containing heteroring occupies two positions on the pyrazole ring. We conjecture that 2*H*-1,4,5-thiadiazocin-7(8*H*)-one is indeed formed and subsequently tautomerizes to 4*H*-1,4,5-thiadiazocin-7(8*H*)-one (for example, **5a** $\rightarrow$ **8** as outlined in Scheme 3). This enamine intermediate then undergoes a transannular anti-Michael addition to the diphenylmethylenone moiety to give **9**. Ring opening via thiolate elimination delivers 1*H*-pyrazol-4(5*H*)-one **10** and subsequent intramolecular thiolate Michael addition gives the observed 4*H*-pyrazolo[5,1-*c*]thiazine (**7a**). Clearly, our switch from benzylidenone-containing **1** to diphenylmethylenone-containing **2** met the initial objective of precluding alkoxide Michael addition and subsequent formation of pyrazole **6**. However, the inherent steric encumbrance of the diphenylmethylenone moiety drives the conversion of, for example, [**5a**] to **7a**, the thermodynamic product of this reaction.

As illustrated in Figure 2, enamine **8** adopts a crown-like conformation in which steric interactions between the diphenylmethylene and carbonyl moieties are minimized by causing the C=C and C=O to become significantly non-coplanar. Furthermore, this conformation places the enamino nitrogen (e.g., N4 in **8**) in close proximity to C8 and hence well positions it for a transannular anti-Michael addition to form the pyrazolo[5,1-*b*]thiazol-7(7*aH*)-one] intermediate **9**. Ring-opening to **10** and subsequent Michael addition delivers **7**. This anti-Michael attack by the enamino nitrogen at C8 is, to some extent, analogous to the recent synthesis of some annulated pyrazoles from a cyclocondensation of arylhydrazines with α -oxoketene.^{1a} It is of relevance to point out that anti-Michael addition examples predominantly involve additions to triple bonds⁵ with anti-Michael additions to double bonds being quite rare.⁶ While we were preparing this manuscript, Suzuki *et al.* reported another example of an anti-Michael addition reaction to a C,C-double bond.^{6c} Our finding which, to our knowledge, constitutes the third report of an anti-Michael addition to a double bond, bears close resemblance to the reported addition of *n*-BuLi to enamido **11** to give **12** (Scheme 4).^{6a}

In conclusion, we have demonstrated (i) a synthesis of the unknown 4*H*-pyrazolo[5,1-*c*]thiazine heterocycle, (ii) the second example of a transannular reaction in an 8-membered S,N,N-heterocycle,⁷ and (iii) discovered another example of the rare anti-Michael addition to a C,C-double bond.

Representative procedure for **2** + **3a–c** $\rightarrow$ **7a–c**: Preparation of 2,7-Bis(4-bromophenyl)-4,4-diphenyl-4*H*-pyrazolo[5,1-*c*][1,4]thiazin-3-ol (**7b**)

To a mixture of thietanone **2** (45mg, 0.18 mmol) and tetrazine **3b** (140mg, 0.36 mmol) in THF (6 mL) was added 5% KOH/MeOH (2 mL). The mixture was stirred for 10 min at which time TLC showed complete disappearance of thietanone **2**. Another three portions of

thietanone (3×0.18 mmol) were added over a 5 min interval. The mixture was then diluted with water and made slightly acidic with 3N HCl (in case of the reaction with 3,6-di-2-pyridyl-[1,2,4,5]tetrazine **2c**, the work up was not made acidic) and extracted with DCM ($3\times$). The combined organic layer was washed with brine, dried over Na_2SO_4 , and evaporated to dryness. Flash chromatography with 10–15% EtOAc/hexane delivered **7b** as a brown oil (114mg, 52 %).

7a: (56%) IR (neat) 3527 cm^{-1} . ^1H NMR (CDCl_3) δ 7.9 (2H, br d, $J = 8.4$ Hz), 7.4 (18H, m), 5.9 (1H, s), 3.1 (1H, br s). ^{13}C NMR (CDCl_3) δ 57.2, 103.7, 125.0, 126.8, 127.9, 128.2, 128.5, 128.8, 128.9, 129.1, 129.6, 132.1, 134.4, 135.7, 139.3, 139.9, 140.3.

7b: (52%) IR (neat) 3522 cm^{-1} . ^1H NMR (CDCl_3) δ 7.7 (2H, d, $J = 8.8$ Hz), 7.4–7.3 (14H, m), 7.2 (H, d, $J = 8.8$ Hz), 5.8 (1H, s), 3.1 (1H, br s). ^{13}C NMR (CDCl_3) δ 57.8, 104.6, 122.0, 123.0, 125.1, 128.3, 129.1, 129.2, 129.5, 130.3, 131.0, 131.5, 131.7, 133.1, 135.8, 138.1, 139.0, 140.0.

7c: (52%) IR (neat) H-bonded OH $3400\text{--}3300\text{ cm}^{-1}$ (w). ^1H NMR (CDCl_3) δ 8.6 (1H, d, $J = 4.8$ Hz), 8.3 (1H, d, $J = 4.8$ Hz), 7.8 (1H, d, $J = 8.0$ Hz), 7.7 (2H, m), 7.6 (1H, d, $J = 8.0$ Hz), 7.4 (4H, m), 7.3–7.2 (7H, m), 7.1 (1H, m), 6.8 (1H, s). ^{13}C NMR (CDCl_3) δ 57.6, 110.4, 119.3, 122.4, 123.1, 123.7, 124.7, 128.1, 128.2, 129.8, 135.8, 136.1, 137.0, 137.5, 140.0, 141.1, 147.3, 149.4, 151.5, 153.7. X-ray data: colorless, triclinic, space group $P1$; $a = 6.5984(3)$, $b = 9.4762(5)$, $c = 18.8062(10)$ Å, $\alpha = 86.689(1)^\circ$, $\beta = 87.781(1)^\circ$, $\gamma = 71.69(1)^\circ$, $V = 1114.27(10)$ Å³, $T = 93(1)$ K, $Z = 2$; 7150 reflections; $R = 0.0418$ for 6006 with $I > 2\sigma(I)$, $R = 0.0515$ for all. Data collection: Bruker SMART Apex 2 diffractometer. Solution and refinement: SHELXS97 and SHELXL97.⁸

Acknowledgments

The authors would like to thank the National Science Foundation (CHE-0614756) and the National Institutes of General Medical Sciences (GM076151) for their support of this work. The NMR spectrometers used in this study were funded in part by grants from the NSF (CHE-9808183) and NIH (RR-11973).

References

1. a) Peruncheralathan S, Khan TA, Illa H, Junjappa H. *J. Org. Chem.* 2005; 70:10030–5. [PubMed: 16292836] b) References cited in 1a. c) Genin MJ, Biles C, Keiser BJ, Swaney SM, Tarpley WG, Yagi Y, Romero DL. *J. Med. Chem.* 2000; 43:1034–40. [PubMed: 10715167] d) Marala RB, Brown JA, Kong JX, Tracey WR, Knight DR, Wester RT, Sun D, Kennedy SP, Hamanaka ES, Ruggeri RB, Hill RJ. *Eur. J. Pharmacol.* 2002; 451:37–41. [PubMed: 12223226] e) Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM, Rogers RS, Rogier DJ, Yu SS, Anderson GD, Burton EG, Cogburn JN, Gregory SA, Koboldt CM, Perkins WE, Seibert K, Veenhuizen AW, Zhang YY, Isakson PC. *J. Med. Chem.* 1997; 40:1347–65. [PubMed: 9135032]
2. Suen YF, Hope H, Nantz MH, Haddadin MJ, Kurth MJ. *J. Org. Chem.* 2005; 70:8468–71. [PubMed: 16209593]
3. a) Haddadin MJ, Agha BH, Salka S. *Tetrahedron Lett.* 1984; 54:2577–80. b) Robins LI, Carpenter RD, Fettingner JC, Haddadin MJ, Tinti DS, Kurth MJ. *J. Org. Chem.* 2006; 71:2480–5. [PubMed: 16526800]
4. a) Amorese A, Arcadi A, Bermocchi E, Cashi S, Cerrini S, Fedeli W, Ortari GO. *Tetrahedron.* 1989; 45:813–28. b) Krubsack AJ, Higa T, Slack WE. *J. Am. Chem. Soc.* 1970; 92:5258–9.
5. a) Back TG, Bethell RJ, Parvez M, Wehrli D. *J. Org. Chem.* 1998; 63:7908–19. b) Back TG, Wehrli D. *Tetrahedron Lett.* 1995; 36:4737–40. c) Gerold A, Krause N. *Chem. Ber.* 1994; 127:1547–9. d) Rudolf WD, Schwarz R. *Synlett.* 1993:369–74.

6. a) Klumpp GW, Mierop AJC, Vrielink JJ, Brugman A, Schakel M. J. Am. Chem. Soc. 1985; 107:6740–2. b) Martin V, Molines H, Wakselman C. J. Org. Chem. 1992; 57:5530–2. See Scheme 5 in: c) Takemura I, Matsumoto T, Suzuki K. Tetrahedron Lett. 2006; 47:6677–9.
7. The first example was reported recently: Khlebnikov AF, Novikov MS, Shinkevich EY, Vidovic D. Org. Biomol. Chem. 2005; 3:4040–2. [PubMed: 16267578]
8. Sheldrick GM. 1997 University of Göttingen Germany b) Crystallographic data (excluding structure factors) for **7c** have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication number CCDC 617978. Copies of the data can be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK [fax: +44(0)-1223-336033 or deposit@ccdc.cam.ac.uk].

Scheme 1.

1,4,5-Thiadiazocinones (5) → pyrazoles (6; R¹ = H) and pyrazolo[5,1-c]thiazines (7; R¹ = C₆H₅).

Scheme 2.
Preparation of thietan-3-one **2**.

Scheme 3.
Proposed mechanism for **[5a]** → **7a**.

Scheme 4.
Anti-Michael addition to acrylamide **11**.

Figure 1. Atomic displacement ellipsoid plot (70% probability) of **7c**. With the exception of S5 and C6, the central, fused heterocycle is planar. S5 and C6 are 1.11 Å and 0.54 Å out of plane, respectively.

Figure 2.
A stereoview of the preferred conformation of 4*H*-1,4,5-thiadiazocin-7(8*H*)-one **8**.